SOBI posts strong growth in 2015 sales and earnings

26 February 2016

Nordic drugmaker Swedish Orphan Biovitrum (STO: SOBI) saw its shares fall 3.3% to 106.40 Swedish kronor in mid-morning trading, after the company released financial results, showing that total net revenue for the fourth quarter of 2015 has increased 15% (+9% at constant currencies) to 814 million kronor ($96.2 million).

Product revenue was 698 million kronor, an increase of 21% (+13% at CC), with gross margin at 64% versus 60% a year earlier. Earnings before interest and tax (EBIT) were 90 million kronor, versus 38 million kroner in the like 2014 quarter.

For full-year 2015, total revenue increased 24% (+14% at CC) to 3.23 billion kronor, with Orfadin (nitisinone) and Kineret (anakinra) delivering strong performance. Product revenue was 2.57 billion kronor, up 29% (+18% at CC), and gross margin was 62% versus 59% for 2014. EBIT came in at 433 million kroner compared with a loss of 43 million kroner for 2014.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK